Atara Biotherapeutics, Inc.
ATRA
$9.81
$1.0311.73%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 20.85% | -280.27% | -93.72% | 399.46% | 42.06% |
| Total Depreciation and Amortization | 208.82% | -508.47% | -86.85% | 63.18% | -10.57% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -140.69% | 18.62% | -80.03% | 48.74% | -5.93% |
| Change in Net Operating Assets | 74.94% | 38.32% | 84.45% | -266.49% | -441.44% |
| Cash from Operations | 41.79% | -33.74% | 73.99% | -14.99% | -513.46% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | 1,161.36% | -87.39% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 419.88% | 54.51% | -131.51% | 396.22% | 120.80% |
| Cash from Investing | 448.62% | 52.25% | -129.48% | 409.45% | 120.26% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 100.00% | -6.38% | -19.29% |
| Issuance of Common Stock | 884.08% | 150,700.00% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -3,119.74% | -103.01% | -- | -- | -241.19% |
| Cash from Financing | -100.29% | -93.16% | 6,221.60% | 23.78% | -100.92% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 124.55% | -482.75% | 126.06% | 47.77% | -241.51% |